anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
All sub-acute rehabilitation patients will be approached for study participation one day prior to discharge day from the facility. Patients will be approached in their private room within the facility to obtain consent. Consent will be reviewed with patient by investigators. Patients will be asked to demonstrate understanding of the study and what consent will imply utilizing the teach back method. If patient is able to demonstrate understanding and gives consent the MoCA will be administered. If MoCA scores falls between 22-30 they will be included in study. If MoCA score falls below 22 they will not be included in study and that will be explained to them at that time. MoCA scores will be included in patient medical record. Patient name and assigned ID number, phone number, second contact and consent will be recorded on the confidential roster sheet and stored in a locked file cabinet located in director's office at Peconic Landing. The day of discharge patients will complete the RHDS survey. Investigators will complete the study data sheet including ID number, MoCA score, RHDS score, length of stay, discharge date, and recommended discharge therapy- home care, outpatient, none. Thirty to thirty-seven days after discharge investigators will call patient and ask 3 questions from scripted form. "How many falls have you had since discharge home:, "How many visits to the emergency room have you had since your discharge home","How many admissions to the hospital have you had since your discharge home." Following completion of telephone questions, confidential roster sheet and consent form will be shredded.
The invention relates to corticotropin-B, its acid addition salts, to a polypeptide composition containing corticotropin-B and/or an ACTH-active derivative or corticotropin-B and to their production from pituitary gland material.  The crude material may be extracted with hydrochloric acid-acetone or methanolacetic acid and the extract contacted with oxycellulose in order to adsorb the ACTH-active substances thereon.  The oxycellulose adsorbate is eluted with a dilute mineral acid solution such as O-IN hydrochloric acid.  The pH of the eluate is adjusted to 2,5 to 3 by contacting it with a strongly basic anion exchange resin in its carbonate form and after removal of the resin by filtration the filtrate is concentrated.  The concentrate is digested with pepsin and treated with trichloracetic acid to precipitate substances of high molecular weight and low ACTH activity.  After clarification the aqueous solution is extracted with a water-immiscible organic solvent and then lyophilized.  The "pepsin-digested material" so obtained is passed in aqueous solution down a column of a carboxylic cation exchange resin such as a dihydroxybenzoic acid-formaldehyde condensate or a copolymer of a polymerizable acid and a divinyl compound such as acrylic or methacrylic acid and divinyl-benzene.  It is preferred to add a mild reducing agent such as hydrogen sulphide, sodium sulphite, thioglycollic acid or cysteine to the aqueous solution, and to use a resin in which about 15 per cent is in the sodium salt form, the remainder being the free-acid.  After washing the column, the resin adsorbate is eluted with aqueous mineral acid (HCC) of pH greater than 1,8 whereby low ACTH-active substances and substances of a lower basicity than corticotropin-B are removed. It is then eluted with aqueous mineral acid of pH from 0,0 to 1,8 whereby corticotropin-B and substances of similar basicity are removed from the resin. Lyophilization of this eluate gives a polypeptide composition containing corticotropin-B and having approximately 300 times the ACTH-activity of Armour Standard La-1-A.  Corticotropin-B may be separated from this composition by means of the Craig counter-current distribution procedure using the system s-butyl alcohol-0,5 per cent aqueous trichloracetic acid.  A detailed description of the complete procedure is given.
BACKGROUND: Many radiology programs utilize a night-float system to mitigate the effects of fatigue, improve patient care, and provide faster report turnaround times. Prior studies have demonstrated an increase in discrepancy rates during night-float shifts.
OBJECTIVES: This study was performed to examine the effects of night-float shift work on radiology resident cognition. We hypothesized that there would be diminished cognitive function on testing following night-float shifts when compared to testing following day shifts.
METHODS: Diagnostic radiology residents in their second to fifth years of residency at a single institution were recruited to participate in this pilot study. Cognitive function was evaluated using the Lumosity Neurocognitive Performance Tests (NCPT), standardized performance tests that provide real-time, objective measurements of cognitive function. Study participants completed the NCPT in 5 sessions following 5 consecutive day shifts to evaluate their baseline cognitive function. The tests were re-administered at the end of consecutive night-float shifts to assess for any changes. Sleep was objectively monitored using actigraphy devices worn around the wrist during all study weeks. Descriptive and summary statistics were performed.
RESULTS: 23 prospectively recruited diagnostic radiology residents working night-float shifts took a mean 13.6 (± 5.1) neurocognitive performance tests during the study period. There was a statistically significant decline in 2 of the 6 cognitive tests administered, signifying a decrease in attention, speed, and complex reasoning ability. Night-float shifts were significantly longer than the day shifts and associated with a significantly higher study volume and cross-sectional study volume. Fitbit data demonstrated that there were no significant differences in level of activity while awake. However, participants slept significantly longer during day shifts.
CONCLUSIONS: A sample of 23 radiology residents working night-float shifts demonstrated declines in attention, speed, and complex reasoning ability following sequential administration of standardized neurocognitive performance tests. While the sample size is small, these findings demonstrate the potential deleterious effects of night-float shift work and provide evidence to support further inquiry into this phenomenon.
Peripheral venous blood samples will collected at two time points as follows: before the premedication and the induction of anesthesia (T₁): 120 minutes after the beginning of anesthesia (T₂). DNA will be obtained from blood samples , and global DNA methylation analysis will be done.
The invention discloses a preparation method of a modified recombinant human acidic fibroblast growth factor and application of the modified recombinant human acidic fibroblast growth factor in skin repair, and relates to the technical field of biology. The invention provides a recombinant human acidic fibroblast growth factor (EGF) protein, the amino acid sequence of which is shown as SEQ ID NO. 2. The inventor of the application accurately carries out reconstruction based on wild aFGF by using a protein engineering technology to obtain recombinant human acidic fibroblast growth factor reconstruction protein with an amino acid sequence shown as SEQ ID NO. 2. Compared with wild type aFGF, the recombinant human acidic fibroblast growth factor modified protein disclosed by the invention has the advantages that (1) the stability is better, and the recombinant human acidic fibroblast growth factor modified protein is not easy to denature and inactivate; (2) Has good transdermal property, can promote the regeneration of epidermal cells, and repair the damage of skin barrier; (3) Has strong oxidation resistance and free radical scavenging effects, and can promote the regeneration of epidermal cells to repair skin barrier, and relieve the symptoms of sensitive redness of skin.
Charcot-Marie-Tooth disease (CMT) rarely presents with painful symptoms, which mainly occur in association with myelin protein zero (MPZ) gene mutations. We aimed to further characterize the features of painful neuropathic phenotypes in MPZ-related CMT. We report on a 58-year-old woman with a longstanding history of intermittent migrant pain and dysesthesias. Examination showed minimal clinical signs of neuropathy along with mild changes upon electroneurographic examination, consistent with an intermediate pattern, and small-fiber loss upon skin biopsy. Genetic testing identified the heterozygous variant p.Trp101Ter in MPZ. We identified another 20 CMT patients in the literature who presented with neuropathic pain as a main feature in association with MPZ mutations, mostly in the extracellular MPZ domain; the majority of these patients showed late onset (14/20), with motor-nerve-conduction velocities predominantly in the intermediate range (12/20). It is hypothesized that some MPZ mutations could manifest with, or predispose to, neuropathic pain. However, the mechanisms linking MPZ mutations and pain-generating nerve changes are unclear, as are the possible role of modifier factors. This peculiar CMT presentation may be diagnostically misleading, as it is suggestive of an acquired pain syndrome rather than of an inherited neuropathy.
Atezolizumab will be administered intravenously at a dose of 1680 milligrams (mg) on Day 1 of each 28-day cycle for 12 cycles or up to 1 year (whichever occurs first). Atezolizumab will be discontinued in the event of IRF-assessed disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor.
Record the following indicators before and after intervention, including height, weight, BMI, blooAccording to previous literature, dapagliflozin has a weight loss effect on overweight/obese individuals. This study is a prospective, open label, single arm, exploratory clinical trial, expected to include 36 overweight women. The subjects enter a 4-week introduction period, during which they need to maintain their original dietary habits and record a 24-hour dietary review on the 3rd of each week. At the end of the introduction period, if the weight change of the subject is less than 3%, it is considered qualified. Then, qualified subjects will receive a 12 week intervention with dapagliflozin tablets (oral, 10mg, once a day). During the experiment, participants were required to maintain their original dietary habits unchanged. Participants are required to record their dietary habits for three days a week in order to determine their energy intake and carbohydrate energy ratio. d pressure, waist circumference, abdominal circumference, waist to hip ratio, morning urine routine, 24-hour urine glucose, fasting blood glucose, fasting insulin, blood lipids (TG/TC/LDL/HDL), body fat percentage, body fat mass, muscle mass, subcutaneous fat, visceral fat volume, and abdominal fat volume, and record any adverse reaction events that occurred during the study. Collect patient urine and serum samples for testing. Collect patient feces, freeze the samples in a -80 ℃ freezer, and send the feces to a biological company for testing of intestinal microbiota composition.

Conduct subgroup analysis, based on the 24-hour dietary review provided by the subjects on the 3rd day of the week during the introduction period, subjects with carbohydrate energy greater than or equal to 26% of their daily energy intake will be included in the non low carbohydrate group (NCD group), and subjects with carbohydrate energy accounting for 10-25% of their daily energy intake will be included in the low carbohydrate group (LCD group).
Spinocerebellar ataxia type 6 (SCA6) is a neurodegenerative disease that manifests in midlife and progressively worsens with age. SCA6 is rare, and many patients are not diagnosed until long after disease onset. Whether disease-causing cellular alterations differ at different disease stages is currently unknown, but it is important to answer this question in order to identify appropriate therapeutic targets across disease duration. We used transcriptomics to identify changes in gene expression at disease onset in a well-established mouse model of SCA6 that recapitulates key disease features. We observed both up- and down-regulated genes with the major down-regulated gene ontology terms suggesting mitochondrial dysfunction. We explored mitochondrial function and structure and observed that changes in mitochondrial structure preceded changes in function, and that mitochondrial function was not significantly altered at disease onset but was impaired later during disease progression. We also detected elevated oxidative stress in cells at the same disease stage. In addition, we observed impairment in mitophagy that exacerbates mitochondrial dysfunction at late disease stages. In post-mortem SCA6 patient cerebellar tissue, we observed metabolic changes that are consistent with mitochondrial impairments, supporting our results from animal models being translatable to human disease. Our study reveals that mitochondrial dysfunction and impaired mitochondrial degradation likely contribute to disease progression in SCA6 and suggests that these could be promising targets for therapeutic interventions in particular for patients diagnosed after disease onset.
PCT No. PCT/JP94/01266 Sec. 371 Date Mar. 14, 1996 Sec. 102(e) Date Mar. 14, 1996 PCT Filed Aug. 1, 1994 PCT Pub. No. WO95/07898 PCT Pub. Date Mar. 23, 1995Provision of a succinamic acid compound of the formula (1)    <IMAGE>  (1)  wherein R1 is an alkyl or a lower alkenyl and R2 is an optionally esterified carboxyl, a pharmaceutically acceptable salt thereof, an agent for the prophylaxis and/or treatment of the complications of diabetes, comprising, as an active ingredient, the succinamic acid compound or a pharmaceutically acceptable salt thereof, an aldose reductase inhibitor comprising, as an active ingredient, the succinamic acid compound or a pharmaceutically acceptable salt thereof, and a method for producing the succinamic acid compound or a pharmaceutically acceptable salt thereof. The novel succinamic acid compounds of the formula (1) of the present invention and pharmaceutically acceptable salts thereof have a strong aldose reductase activity-inhibitory in mammals such as human, and show superior safety. Hence, they are useful as pharmaceutical agents for the treatment of the complications of diabetes such as faulty union of corneal injury, cataract, neurosis, retinopathy and nephropathy, in particular, cataract and neurosis. According to the production method of the present invention, efficient production of such useful compounds of the present invention can be provided.
Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week, the participant will be asked to choose whether to keep, give, or split the reward, if they meet or exceed their goal. If they choose to send some of the money to charity, they will be asked to identify a charity to which they would like to donate the payment. If they meet their goal, they will receive money and/or be notified that a donation of the selected amount has been sent to the charity, depending on their selected preference. Incentives are terminated after 4 months. Daily use of pedometer continues for an additional 4 weeks.
Impulsivity has been proposed to have an impact on glycemic dysregulation. However, it remains uncertain whether an unfavorable glycemic status could also contribute to an increase in impulsivity levels. This study aims to analyze associations of baseline and time-varying glycemic status with 3-year time-varying impulsivity in older adults at high risk of cardiovascular disease. A 3-year prospective cohort design was conducted within the PREDIMED-Plus-Cognition substudy. The total population includes 487 participants (mean age = 65.2 years; female = 50.5%) with overweight or obesity and metabolic syndrome. Insulin resistance (HOMA-IR), glycated hemoglobin (HbA1c), presence of type 2 diabetes mellitus, and type 2 diabetes control were evaluated. Impulsivity was measured using the Impulsive Behavior Scale questionnaire and various cognitive measurements. Impulsivity z-scores were generated to obtain Global, Trait, and Behavioral Impulsivity domains. Linear mixed models were used to study the longitudinal associations across baseline, 1-year, and 3-year follow-up visits. HOMA-IR was not significantly related to impulsivity. Participants with higher HbA1c levels, type 2 diabetes, and poor control of diabetes showed positive associations with the Global Impulsivity domain over time, and those with higher HbA1c levels were further related to increases in the Trait and Behavioral Impulsivity domains over the follow-up visits. These results suggest a potential positive feedback loop between impulsivity and glycemic-related dysregulation.
A conditionally replicating, aneurovirulent recombinant herpes simplex virus is provided that includes a nucleic acid encoding an expressible chemokine. An expression control element is operably linked to the nucleic acid. A therapeutic composition includes a first conditionally replicating, aneurovirulent recombinant herpes simplex virus having a first nucleic acid encoding a first expressible cytokine operatively linked to an expression control element. A second such herpes simplex virus encoding a second expressible cytokine is also provided with a pharmaceutically acceptable carrier. Preferably, the second cytokine is a chemokine. In a particular embodiment, the first expressible cytokine increases availability of an immunoresponsive cell for activation. The activatable cell is CD4+, CD8+, NK, a dendritic cell, or a combination thereof. A second conditionally replicating, aneurovirulent, recombinant herpes simplex virus expresses a second cytokine in the same host cell as the first virus or alternatively, upon expression in a second host cell, resulting in the activation of the immunoresponsive cell. A method of tumor cell growth inhibition is provided that includes introduction of a therapeutically effective amount of an aforementioned therapeutic composition into a tumor of an individual such that two different cytokines are produced within the tumor to enhance the immune response in the individual that inhibits tumor cell growth. The first and second recombinant herpes simplex viruses are administered simultaneously, sequentially. Sequential administration is separated by a time period ranging from a few second to several days.
Lung metastasis poses a formidable challenge in the realm of cancer treatment, with conventional chemotherapy often falling short due to limited targeting and low accumulation in the lungs. Here, we show a microrobot approach using motile algae for localized delivery of drug-loaded nanoparticles to address lung metastasis challenges. The biohybrid microrobot [denoted "algae-NP(DOX)-robot"] combines green microalgae with red blood cell membrane-coated nanoparticles containing doxorubicin, a representative chemotherapeutic drug. Microalgae provide autonomous propulsion in the lungs, leveraging controlled drug release and enhanced drug dispersion to exert antimetastatic effects. Upon intratracheal administration, algae-NP(DOX)-robots efficiently transport their drug payload deep into the lungs while maintaining continuous motility. This strategy leads to rapid drug distribution, improved tissue accumulation, and prolonged retention compared to passive drug-loaded nanoparticles and free drug controls. In a melanoma lung metastasis model, algae-NP(DOX)-robots exhibit substantial improvement in therapeutic efficacy, reducing metastatic burden and extending survival compared to control groups.
FIELD: virology. SUBSTANCE: invention relates to the strain of avian influenza A virus. Proposed strain, in contrast to other strains with subtype of hemagglutinine H5, shows no pathogenicity for birds and humans. Adapted strain is obtained by passages of the parent virus A/mallard duck/Pennsylvania/10218/84 (H5N2) through white mice lungs. Obtained strain is designated for research of genetic bases of interspecies barrier overcoming, detection of phylogenetic and ecological association of viruses isolated for different times in different geographic regions. Claimed influenza virus damages mouse lung that are identified as viral bronchopneumonia that resembles by many traits with human viral bronchopneumonia. Strain of avian influenza A virus (H5N2) is stored in collection of laboratory of museum strains of Institute of virology RAMS-GKV at N 2340. EFFECT: strain of influenza virus A indicated above, valuable properties. 3 tbl, 1 ex
The study is a randomized, parallel group, unblinded, multicenter study that compares two approaches \[home-based, portable monitoring (PM) versus attended, laboratory-based polysomnography (PSG) (Lab)\] in adults, at least 18 years of age, with a moderate to high probability of obstructive sleep apnea (OSA) and who have been referred to sleep medicine specialists at AASM-accredited sleep centers for evaluation and/or management. The study is designed to compare the utility of the two approaches (PM group vs. Lab group) for the diagnosis and management of OSA in adults. Approximately 372 eligible adults will be randomized at screening to either the PM or Lab arm (186 per arm), undergo baseline OSA testing to confirm diagnosis and study eligibility, then receive positive airway pressure (PAP) titration studies to determine the level of pressure needed to treat their OSA. For qualifying participants, the titration study will be lab-based in the Lab group and be home-based using a commercially available portable, automatic PAP device (APAP) in the PM group. All qualifying study participants will have access to study CPAP equipment and supplies to treat their OSA. Primary outcomes (time from diagnosis to effective treatment, patient outcomes, and relative resource utilization) are determined at 1 and 3 months after starting CPAP treatment. Study participants who complete all of their study visits will keep their CPAP machine at the end of the study.
The swallow function is a multidirectional process that depends on complex neuro-muscular network. The function can be evaluated using instrumental, such as fibreoptic endoscopic evaluation of swallowing (FEES), videofluoroscopy, or well structured questionnaires. There are many questionnaire and scales for assessment of swallow but very few have been validated. The study will assess the construct validity and reliability of the Turkish version of Self-report Symptom Inventory as known as Sydney Swallow Questionnaire. The investigators developed the Turkish version of this questionnaire (SSQ-T), according to the cross-cultural adaptation guidelines. Two translators translated the SSQ into Turkish and a native English language speaker reverse-translated it into English. The back translation was sent to the original author for proofreading. The SSQ questionnaire consisted of 17 basic questions related with dysphagia symptoms.
NEW MATERIAL:A compound shown by the formula I [R is (halogen-substituted) 1-5C alkyl, substituted silyl, benzyl, benzhydryl, or trityl (with the proviso that phenyl nucleus of the group may be replaced with methyl, methoxy, or nitro)]. EXAMPLE:(+ or -)-6,7-Cis-7-phthalimido-1-azabicyclo[4, 2, 0]oct-2-ene-3-formyl-3-oxo-2- carboxylic acid tertiary butyl ester. USE:An intermediate for antibacterial compound. PREPARATION:A nitro derivative shown by the formula III is reacted with titanium trichloride in a mixed system of an aqueous solution and an organic solvent such as methanol, THF, DMF, etc. at 0-30 deg.C, to give an aldehyde derivative shown by the formula IV. This compound is then treated with a halogenating agent such as pyrrolidone hydrotribromide, etc., and a halogen is introduced into the treated compound at alpha-position. The resultant compound is dehydrohalogenated with a base.